Please login to the form below
Stelara
This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.
NICE’s fast-track catapults Skyrizi into market
NICE noted in its final appraisal in June that clinical trials shows Skyrizi is more effective than AbbVie’s Humira (adalimumab) and J&J’s IL-12/IL-23 inhibitor Stelara ... Of the newer agents, Stelara was the most prescribed, with expenditure at
Latest news
-
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
Abbvie’s Humira (adalimumab) and J&J’s Stelara (ustekinumab) remain the leaders in the market due to the strength of their ability to quickly clear up to 75% of lesions
-
Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
AbbVie’s Humira (adalimumab) and J&J’s Stelara (ustekinumab) became, and remain, big selling drugs partly on the strength of their ability to quickly clear up to 75% of lesions
-
AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
Of the newer agents, Stelara was the most prescribed, with expenditure at £32m for the period, up 25%. ... This reflects a global picture, with Stelara expected to maintain its lead among the newer agents, Evaluate expecting its sales to global annual
-
Tremfya heads for filing in psoriatic arthritis
Tremfiya (guselkumab) is the follow-up to J&J’s IL-23/IL-12 inhibitor blockbuster Stelara, which is under assault from rival new entrants across immunology indications, most notably Novartis’ ... Cosentyx. While Stelara remains in a solid second
-
Latecomer Lilly preps its IL-23 drug for Crohn’s disease
First to market was Johnson &Johnson’s dual IL-12/IL-23 inhibitor Stelara (ustekinumab) for psoriasis, which rapidly achieved blockbuster status with add-on indications in psoriatic arthritis and ... already FDA-approved for psoriasis and require fewer
More from news
Approximately 14 fully matching, plus 65 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
-
Taking a strategic approach
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
-
Back to the future
Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Attigo (part of the Mednet Group)
We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
